Huada Gene released its 2017 semi-annual report: revenue of 900 million in the first half of the year and net profit of 200 million
Today (August 30), Huada Gene (300676) released its 2017 semi-annual report. The announcement shows that the company achieved operating income of 889 million yuan in the first half of the year, an increase of 15.90% over the same period of the previous year; net profit of 203 million yuan, compared with The year-on-year growth was 28.08%; the net profit attributable to shareholders of listed companies was 163 million yuan, an increase of 50.07% over the same period of the previous year.
According to the announcement, in the main business of Huada Gene, all major business segments have achieved varying degrees of growth. Among them, the key strategic business sector basic research and clinical application services grew steadily. As of June 30, the company has completed more than 2.2 million non-invasive prenatal genetic tests, with detection rates and specificities greater than 99%, and operating income of 5.11. 100 million yuan, an increase of 22.54% over the same period of last year; gross profit margin of 75.94%, an increase of 0.79% over the same period of the previous year.
The other three sectors also maintained growth. The basic scientific research services achieved operating income of approximately 170 million yuan in the first half of the year, an increase of 12.14% over the same period of the previous year; the gross profit margin was 44.29%, an increase of 2.03% over the same period of the previous year. In the first half of the year, basic research and clinical application services for complex diseases achieved operating income of 167 million yuan, an increase of 2.82% over the same period of the previous year; gross profit margin was 38.26%, an increase of 1.74% over the same period of the previous year. The basic income of drug research and clinical application services reached 36.356 million yuan, an increase of 22.79% over the same period of last year; the gross profit margin was 45.87%, an increase of 15.47% over the same period of the previous year.
In its semi-annual report, Huada Gene said that it has formed a business layout covering the whole country and radiating the world, covering more than 100 countries and regions in the world, including more than 2,000 scientific research institutions and more than 2,300 medical institutions in 31 provinces, municipalities and autonomous regions. There are more than 300 institutions in the top three hospitals; more than 3,000 overseas medical and scientific research institutions cooperate in Europe, America, Oceania and other regions.
In the first half of the year, Huada Gene signed a comprehensive cooperation agreement with many hospitals such as the International Peace Maternal and Child Health Hospital affiliated to Shanghai Jiao Tong University School of Medicine and the First Hospital of Shanxi Medical University, and it was associated with Fuyang City, Anhui Province, Qingdao City, Shandong Province, and Taian City, Shandong Province. The city, the Lhasa Autonomous Region of Tibet and other governments signed a strategic cooperation agreement covering non-invasive prenatal genetic testing, neonatal genetic testing, HPV genetic testing, and rapid detection of pathogenic microorganisms. With the support of the local government, the genetic technology has been A Huimin project that serves the people.
In addition, the semi-annual report shows that Huada Gene has established stable tumor gene detection service business cooperation with more than 150 hospitals in China; it has formed stable HLA with more than 110 hospitals and research institutes in China, 20 bone marrow banks and cord blood banks. Business cooperation, the number of samples tested exceeded 446,000.
In terms of research and development, in the first half of 2017, Huada's gene research and development investment was 79.0059 million yuan, an increase of 11.33% over the same period of the previous year. At present, it has obtained more than 100 core technology patents, among which 331 software copyrights have been obtained for the independent software of bioinformatics analysis. Huada Gene said that it will further increase investment in technology research and development, promote the rapid development of technological innovation, and lead the technology service. And the development of precision medicine ; and the gradual upgrading of existing products, accelerate the incubation of a number of industrial projects with good market prospects, and gradually introduce genetic testing services and products in the pathogen field and other disease types.
For the future development, Huada Gene said that it will continue to deepen the strategic layout of global business, further improve the comprehensive technology and the whole industry chain layout in the fields of high-end diagnosis, gene sequencing , cell therapy, gene therapy, etc., and comprehensively upgrade the platform, technology, and optimization. Product structure, building a life science database.
Filter Cartridge
Filter cartridge including : air Filter Cartridge, oil Filter Cartridge, PP Filter Cartridge, string wound Filter Cartridge, stainless steel Filter Cartridge, corrugated Filter Cartridge, spraying Filter Cartridge.
The Filter Cartridge be widely used in vacuum coating, mechanical engineering, CD, metallurgy, petroleum, chemical industry, paper making, food, medicine, electronics, electricity, ceramics, water diversion, printing and dyeing, sugar making .
The advantages of Filter Cartridge :
suitable for filtering strong acid, strong alkali and organic solvents
the area of membrane filtration is large
low diferential pressure, long service life
purifying the air
reduce the noise
save fuel
Filter Cartridge,Water Filter Cartridges,Sediment Filter Cartridge,Iron Water Filter Cartridge
ANPING COUNTY SHANGCHEN WIREMESH PRODUCTS CO.,LTD , https://www.scwiremesh.com